REG - Haleon PLC - Haleon Preliminary 2025 Full Year Results

HALEONAnnouncement

25/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260225:nRSY2433Ua&default-theme=true

RNS Number : 2433U  Haleon PLC  25 February 2026

 

Haleon plc: Preliminary 2025 Full Year Results

 

25 February 2026: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today
announces its preliminary full year results statement for the year ended 31
December 2025 is available at
http://www.rns-pdf.londonstockexchange.com/rns/2433U_1-2026-2-24.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/2433U_1-2026-2-24.pdf) .

 

The preliminary full year results statement will also be available on the
Haleon website www.haleon.com/investors (http://www.haleon.com/investors) ,
and the results have been submitted in full unedited text to the Financial
Conduct Authority's National Storage Mechanism and will shortly be available
for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

 

Dividend

Reflecting the strength of FCF generation during the year, alongside strong
organic operating profit growth, the Board is proposing a 2025 total dividend
of 7.1p per ordinary share which represents a payout ratio of approximately
38% of 2025 adjusted earnings (2024: 37%). This includes a final dividend of
4.9p per ordinary share.

 

Subject to shareholder approval, the final dividend will be paid on 14 May
2026 to holders of ordinary shares and US American Depositary Shares (ADS) on
the register as of 10 April 2026 (the record date). The ex-dividend date for
ordinary shares will be 9 April 2026 and for US American Depositary Shares
(ADS) 10 April 2026. For ordinary shareholders wishing to participate in the
Dividend Reinvestment Programme (DRIP), the election deadline will be 24 April
2026. The DRIP is provided by Equiniti Financial Services Limited, more
information is available at www.shareview.co.uk/info/drip
(http://www.shareview.co.uk/info/drip) .

 

Subject to market conditions and Board approval, Haleon expects to grow its
ordinary dividend at least in line with adjusted earnings.

 

Presentation for analysts and shareholders

A recorded results presentation by Brian McNamara, Chief Executive Officer,
and Dawn Allen, Chief Financial Officer, will be available shortly after
7:00am GMT (8:00 am CET) on 25 February 2026 and can be accessed at
www.haleon.com/investors (http://www.haleon.com/investors) . This will be
followed by a Q&A session at 8:45am GMT (9:45am CET).

 

For analysts and shareholders wishing to ask questions, please use the dial-in
details below which will have a Q&A facility:

 

 UK:         +44 (0) 808 189 0158
 US:         +1 855 979 6654
 All other:  +44 (0) 203 936 2999
 Passcode:   049869

An archived webcast of the Q&A call will be available later on the day of
the results and can be accessed at www.haleon.com/investors
(http://www.haleon.com/investors) .

This information contains regulated information as per 6.3.7R of the
Disclosure and Transparency Rules of the Financial Conduct Authority.

 

Amanda Mellor

Company Secretary

 

Enquiries

 

 Investors                                    Media

 Jo Russell              +44 7787 392441      Zoë Bird           +44 7736 746167
 Rakesh Patel            +44 7552 484646      Victoria Durman    +44 7894 505730
 Email: investor-relations@haleon.com         Email: corporate.media@haleon.com

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans six major categories - Oral Health, Vitamins, Minerals and Supplements
(VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin
Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin,
Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on
trusted science, innovation and deep human understanding.

 

For more information please visit www.haleon.com (http://www.haleon.com) .

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PREUSAWRNOUUUAR



            Copyright 2019 Regulatory News Service, all rights reserved